Compare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AJANTA PHARMA ALKEM LABORATORIES/
AJANTA PHARMA
 
P/E (TTM) x - 22.9 - View Chart
P/BV x 6.6 4.0 164.1% View Chart
Dividend Yield % 0.7 0.9 75.0%  

Financials

 ALKEM LABORATORIES   AJANTA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
AJANTA PHARMA
Mar-19
ALKEM LABORATORIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,422 111.8%   
Low Rs1,232898 137.3%   
Sales per share (Unadj.) Rs417.5233.5 178.8%  
Earnings per share (Unadj.) Rs56.344.0 128.0%  
Cash flow per share (Unadj.) Rs64.752.2 124.1%  
Dividends per share (Unadj.) Rs12.709.00 141.1%  
Dividend yield (eoy) %0.90.8 116.0%  
Book value per share (Unadj.) Rs292.9255.1 114.8%  
Shares outstanding (eoy) m119.5788.02 135.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.45.0 68.0%   
Avg P/E ratio x25.126.4 95.0%  
P/CF ratio (eoy) x21.822.2 98.0%  
Price / Book Value ratio x4.84.5 105.9%  
Dividend payout %22.620.5 110.2%   
Avg Mkt Cap Rs m168,653102,081 165.2%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m9,1714,307 212.9%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m49,91520,554 242.9%  
Other income Rs m1,645211 780.4%   
Total revenues Rs m51,56120,765 248.3%   
Gross profit Rs m8,4825,664 149.8%  
Depreciation Rs m1,006721 139.5%   
Interest Rs m67112 5,781.0%   
Profit before tax Rs m8,4515,143 164.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,273 126.2%   
Profit after tax Rs m6,7313,870 173.9%  
Gross profit margin %17.027.6 61.7%  
Effective tax rate %19.024.8 76.8%   
Net profit margin %13.518.8 71.6%  
BALANCE SHEET DATA
Current assets Rs m27,06211,812 229.1%   
Current liabilities Rs m15,3243,776 405.8%   
Net working cap to sales %23.539.1 60.1%  
Current ratio x1.83.1 56.5%  
Inventory Days Days6777 85.9%  
Debtors Days Days4182 50.6%  
Net fixed assets Rs m12,61014,398 87.6%   
Share capital Rs m239175 136.3%   
"Free" reserves Rs m34,49022,277 154.8%   
Net worth Rs m35,02722,452 156.0%   
Long term debt Rs m1,2127 18,357.6%   
Total assets Rs m54,38726,962 201.7%  
Interest coverage x13.6444.3 3.1%   
Debt to equity ratio x00 11,767.3%  
Sales to assets ratio x0.90.8 120.4%   
Return on assets %13.614.4 94.5%  
Return on equity %19.217.2 111.5%  
Return on capital %24.923.0 108.3%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56310,682 61.4%   
Fx outflow Rs m3,0122,102 143.3%   
Net fx Rs m3,5528,580 41.4%   
CASH FLOW
From Operations Rs m7,2593,748 193.7%  
From Investments Rs m1,864-2,228 -83.7%  
From Financial Activity Rs m-9,273-1,475 628.8%  
Net Cashflow Rs m-15045 -331.9%  

Share Holding

Indian Promoters % 66.9 73.8 90.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 1.6 2,135.5%  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.0 -  
Shareholders   68,381 20,968 326.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   BIOCON   WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 23, 2019 02:55 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS